Cargando…
Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT
Rituximab (RTX) is an anti-CD20 monoclonal antibody that targets B cells—from the immature pre-B-cell stage in the bone marrow to mature circulating B cells—while preserving stem cells and plasma cells. It is used to treat autoimmune diseases, hematological malignancies, or complications after hemat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727997/ https://www.ncbi.nlm.nih.gov/pubmed/35003091 http://dx.doi.org/10.3389/fimmu.2021.773853 |
_version_ | 1784626633974480896 |
---|---|
author | Luterbacher, Fanny Bernard, Fanette Baleydier, Frédéric Ranza, Emmanuelle Jandus, Peter Blanchard-Rohner, Geraldine |
author_facet | Luterbacher, Fanny Bernard, Fanette Baleydier, Frédéric Ranza, Emmanuelle Jandus, Peter Blanchard-Rohner, Geraldine |
author_sort | Luterbacher, Fanny |
collection | PubMed |
description | Rituximab (RTX) is an anti-CD20 monoclonal antibody that targets B cells—from the immature pre-B-cell stage in the bone marrow to mature circulating B cells—while preserving stem cells and plasma cells. It is used to treat autoimmune diseases, hematological malignancies, or complications after hematopoietic stem cell transplantation (HSCT). Its safety profile is acceptable; however, a subset of patients can develop persistent hypogammaglobulinemia and associated severe complications, especially in pediatric populations. We report the unrelated cases of two young men aged 17 and 22, presenting with persistent hypogammaglobulinemia more than 7 and 10 years after treatment with RTX, respectively, and administered after HSCT for hemolytic anemia and Epstein–Barr virus reactivation, respectively. Both patients’ immunological workups showed low levels of total immunoglobulin, vaccine antibodies, and class switched-memory B cells but an increase in naive B cells, which can also be observed in primary immunodeficiencies such as those making up common variable immunodeficiency. Whole exome sequencing for one of the patients failed to detect a pathogenic variant causing a Mendelian immunological disorder. Annual assessments involving interruption of immunoglobulin replacement therapy each summer failed to demonstrate the recovery of endogenous immunoglobulin production or normal numbers of class switched-memory B cells 7 and 10 years after the patients’ respective treatments with RTX. Although the factors that may lead to prolonged hypogammaglobulinemia after rituximab treatment (if necessary) remain unclear, a comprehensive immunological workup before treatment and long-term follow-up are mandatory to assess long-term complications, especially in children. |
format | Online Article Text |
id | pubmed-8727997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87279972022-01-06 Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT Luterbacher, Fanny Bernard, Fanette Baleydier, Frédéric Ranza, Emmanuelle Jandus, Peter Blanchard-Rohner, Geraldine Front Immunol Immunology Rituximab (RTX) is an anti-CD20 monoclonal antibody that targets B cells—from the immature pre-B-cell stage in the bone marrow to mature circulating B cells—while preserving stem cells and plasma cells. It is used to treat autoimmune diseases, hematological malignancies, or complications after hematopoietic stem cell transplantation (HSCT). Its safety profile is acceptable; however, a subset of patients can develop persistent hypogammaglobulinemia and associated severe complications, especially in pediatric populations. We report the unrelated cases of two young men aged 17 and 22, presenting with persistent hypogammaglobulinemia more than 7 and 10 years after treatment with RTX, respectively, and administered after HSCT for hemolytic anemia and Epstein–Barr virus reactivation, respectively. Both patients’ immunological workups showed low levels of total immunoglobulin, vaccine antibodies, and class switched-memory B cells but an increase in naive B cells, which can also be observed in primary immunodeficiencies such as those making up common variable immunodeficiency. Whole exome sequencing for one of the patients failed to detect a pathogenic variant causing a Mendelian immunological disorder. Annual assessments involving interruption of immunoglobulin replacement therapy each summer failed to demonstrate the recovery of endogenous immunoglobulin production or normal numbers of class switched-memory B cells 7 and 10 years after the patients’ respective treatments with RTX. Although the factors that may lead to prolonged hypogammaglobulinemia after rituximab treatment (if necessary) remain unclear, a comprehensive immunological workup before treatment and long-term follow-up are mandatory to assess long-term complications, especially in children. Frontiers Media S.A. 2021-12-22 /pmc/articles/PMC8727997/ /pubmed/35003091 http://dx.doi.org/10.3389/fimmu.2021.773853 Text en Copyright © 2021 Luterbacher, Bernard, Baleydier, Ranza, Jandus and Blanchard-Rohner https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Luterbacher, Fanny Bernard, Fanette Baleydier, Frédéric Ranza, Emmanuelle Jandus, Peter Blanchard-Rohner, Geraldine Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT |
title | Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT |
title_full | Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT |
title_fullStr | Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT |
title_full_unstemmed | Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT |
title_short | Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT |
title_sort | case report: persistent hypogammaglobulinemia more than 10 years after rituximab given post-hsct |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727997/ https://www.ncbi.nlm.nih.gov/pubmed/35003091 http://dx.doi.org/10.3389/fimmu.2021.773853 |
work_keys_str_mv | AT luterbacherfanny casereportpersistenthypogammaglobulinemiamorethan10yearsafterrituximabgivenposthsct AT bernardfanette casereportpersistenthypogammaglobulinemiamorethan10yearsafterrituximabgivenposthsct AT baleydierfrederic casereportpersistenthypogammaglobulinemiamorethan10yearsafterrituximabgivenposthsct AT ranzaemmanuelle casereportpersistenthypogammaglobulinemiamorethan10yearsafterrituximabgivenposthsct AT janduspeter casereportpersistenthypogammaglobulinemiamorethan10yearsafterrituximabgivenposthsct AT blanchardrohnergeraldine casereportpersistenthypogammaglobulinemiamorethan10yearsafterrituximabgivenposthsct |